Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences:
- TD Cowen Immunology and Inflammation Virtual Summit
Date: Wednesday, November 12, 2025
Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT
- Piper Sandler 37th Annual Healthcare Conference
Date: Tuesday, December 2, 2025
Presentation Time: 2:00 p.m. ET / 11:00 a.m. PT
Live webcasts of the presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com . Replays of the events will be available on the Xencor website for at least 30 days following the presentations.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20251110946225/en/
/Facebook-you've%20been%20Zucked%20by%20Annie%20Spratt%20via%20Unsplash.jpg)
